Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/93053
標題: Expression of reduced folate carrier in normal canine tissues and lymphomas
還原葉酸載體在犬正常組織及淋巴瘤的表現
作者: Chun-Yuan Huang
黃俊元
關鍵字: 
NO
引用: Abbo, A.H., Lucroy, M.D., 2007. Assessment of anemia as an independent predictor of response to chemotherapy and survival in dogs with lymphoma: 96 cases (1993-2006). Journal of the American Veterinary Medical Association 231, 1836-1842. Allegra, C.J., Chabner, B.A., Drake, J.C., Lutz, R., Rodbard, D., Jolivet, J., 1985. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. The Journal of Biological Chemistry 260, 9720-9726. Balamurugan, K., Said, H.M., 2006. Role of reduced folate carrier in intestinal folate uptake. American journal of physiology. Cell Physiology 291, 189-193. Barredo, J.C., Synold, T.W., Laver, J., Relling, M.V., Pui, C.H., Priest, D.G., Evans, W.E., 1994. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 84, 564-569. Beaver, L.M., Strottner, G., Klein, M.K., 2010. Response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell lymphoma: 41 cases (2006-2008). Journal of the American Veterinary Medical Association 237, 1052-1055. Bosson, G., 2003. Reduced folate carrier: biochemistry and molecular biology of the normal and methotrexate-resistant cell. British Journal of Biomedical Science 60, 117-129. Botez, M.I., Young, S.N., Bachevalier, J., Gauthier, S., 1982. Effect of folic acid and vitamin B12 deficiencies on 5-hydroxyindoleacetic acid in human cerebrospinal fluid. Annals of Neurology 12, 479-484. Brodsky, E.M., Maudlin, G.N., Lachowicz, J.L., Post, G.S., 2009. Asparaginase and MOPP treatment of dogs with lymphoma. Journal of Veterinary Internal Medicine 23, 578-584. Chango, A., Emery-Fillon, N., de Courcy, G.P., Lambert, D., Pfister, M., Rosenblatt, D.S., Nicolas, J.P., 2000. A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Molecular Genetics and Metabolism 70, 310-315. Chiao, J.H., Roy, K., Tolner, B., Yang, C.H., Sirotnak, F.M., 1997. RFC-1 gene expression regulates folate absorption in mouse small intestine. The Journal of Biological Chemistry 272, 11165-11170. Chu, E., Allegra, C.J., 1996. Antifolates. In: Chabner, B.A., Longo, D.L. (eds.), Cancer Chemotherapy and Biotherapy, second ed. Lippincott-Raven,Philadelphia, USA, pp. 109–148. Chu, E., Callender, M.A., Farrell, M.P., Schmitz, J.C., 2003. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemotherapy and Pharmacology 52, 80-89. Chun, R., 2009. Lymphoma: which chemotherapy protocol and why? Topics in Companion Animal Medicine 24, 157-162. Cohen, M.H., Johnson, J.R., Wang, Y.C., Sridhara, R., Pazdur, R., 2005. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. The Oncologist 10, 363-368. Cosulich, D.B., Hultquist, M.E., Seeger, D.R., 1948. The chemistry of certain pteroylglutamic acid antagonists. Transactions of The New York Academy of Sciences 10, 82-83. Damaraju, V.L., Cass, C.E., Sawyer, M.B., 2008. Renal conservation of folates role of folate transport proteins. Vitamins and Hormones 79, 185-202. DeGraw, J.I., Colwell, W.T., Piper, J.R., Sirotnak, F.M., 1993. Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin. Journal of Medical Chemistry 36, 2228–2231. Ding, B.C., Whetstine, J.R., Witt, T.L., Schuetz, J.D., Matherly, L.H., 2000. Repression of human reduced folate carrier gene expression by wild type p53. The Journal of Biological Chemistry 276, 8713-8719. Dixon, K.H., Lanpher, B.C., Chiu, J., Kelley, K., Cowan, K.H., 1994. A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells. The Journal of Biological Chemistry 269, 17-20. Dobson, J.M., Blackwood, L.B., Mclnnes, E.F., Bostock, D.E., Nicholls, P., Hoather,T.M., Tom, B.D., 2001. Prognostic variables in canine multicentric lymphosarcoma. The Journal of Small Animal Practice 42,377-384. Dorfman, S.K., Hurvitz, A.I., Patnaik, A.K.,1977. Primary and secondary bone tumours in the dog. The Journal of Small Animal Practice 18, 313-326. Emini, E.A., Schleif, W.A., Colonno, R.J., Wimmer, E., 1985. Antigenic conservation and divergence between the viral-specific proteins of poliovirus type 1 and various picornaviruses. Virology 140, 13-20. Endo, Y., Cho, K.W., Nishigaki, K., Momoi, Y., Nishimura, Y., Mizuno, T., Goto, Y.,Watari, T., Tsujimoto, H., Hasegawa, A., 1997. Molecular characteristics of malignant lymphomas in cats naturally infected with feline immunodeficiency virus. Veterinary Immunology and Immunopathology 57, 153-167. Ferguson, P.L., Flintoff, W.F., 1999. Topological and functional analysis of the human reduced folate carrier by hemagglutinin epitope insertion. The Journal of Biological Chemistry 274, 16269-16278. Ferrer, L., Fondevila, D., Rabanal, R., Ramis, A., 1992. Detection of T lymphocytes in canine tissue embedded in paraffin wax by means of antibody to CD3 antigen. methotrexate polyglutamylation and cytotoxicity. Molecular Pharmacology 52, 155-163. Garrett, L.D., Thamm, D.H., Chun, R., Dudley, R., Vail, D.M., 2002. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal of Veterinary Internal Medicine 16, 704-709. Goldman, I.D., Matherly, L.H., 1985. The cellular pharmacology of methotrexate. Pharmacology & Therapeutics 28, 77-102. Goldman, I.D., Zhao, R., 2002. Molecular, biochemical, and cellular pharmacology of pemetrexed. Seminars in Oncology 29, 3-17. Gong, M., Cowan, K.H., Gudas, J., Moscow, J.A., 1999. Isolation and characterization of genomic sequences involved in the regulation of the human reduced folate carrier gene (RFC1). Gene 233, 21-31. Goresky, C.A., Watanabe, H., Johns, D.G., 1963. The renal excretion of folic acid. The Journal of Clinical Investigation 42, 1841–1849. Gorlick, R., Goker, E., Trippett, T., Steinherz, P., Elisseyeff, Y., Mazumdar, M., Flintoff, W.F., Bertino, J.R., 1997. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 89, 1013-1018. Gröne, A., Weckmann, M.T., Capen, C.C., Rosol, T.J.,1996. Canine glyceraldehyde-3-phosphate dehydrogenase complementary DNA: polymerase chain reaction amplification, cloning, partial sequence analysis, and use as loading control in ribonuclease protection assays. American Journal of Veterinary Research 57, 254-257. Guija de Arespacochaga, A., Schwendenwein, I., Weissenböck, H., 2007. Retrospective study of 82 cases of canine lymphoma in Austria based on the Working Formulation and immunophenotyping. Journal of Comparative Pathology 136, 186-192. Hazarika, M., White, R.M., Johnson, J.R., Pazdur, R., 2004. FDA drug approval summaries: pemetrexed (Alimta). The Oncologist 9, 482-488. Hinken, M., Halwachs, S., Kneuer, C., Honscha, W., 2011. Subcellular localization and distribution of the reduced folate carrier in normal rat tissues. European Journal of Histochemistry 55, 10. Honscha, W., Dötsch, K.U., Thomsen, N., Petzinger, E., 2000. Cloning and functional characterization of the bile acid-sensitive methotrexate carrier from rat liver cells. Hepatology 31, 1296-1304. Horne, D.W., 1993. Transport of folates and antifolates in liver. Proceedings of the Society for Experimental Biology and Medicine 202, 385-391. Imahori, S., Moore, G.E., 1972.Multiple myeloma and prolonged stimulation of reticuloendothelial system. New York State Journal of Medicine 72, 1625-1628. Ishii, M., Hashimoto, M., Oguma, K., Kano, R., Moritomo, T., Hasegawa, A., 2006. Molecular cloning and tissue expression of canine Toll-like receptor 2 (TLR2). Veterinary Immunology and Immunopathology 110, 87-95. Jacobs, R.M., Messick, J.B., Valli, V.E., 2002. Tumors of the hemolymphatic system. In: Meuten, D.J. (Ed.), Tumors in Domestic Animals, fourth ed. Blackwell, Iowa, USA, pp. 119-198. Jagielski, D., Lechowski, R., Hoffmann-Jagielska, M., Winiarczyk, S., 2002. A retrospective study of the incidence and prognostic factors of multicentric lymphoma in dogs (1998-2000). Journal of Veterinary Medicine. A, Physiology, pathology, clinical medicine 49, 419-424. Jameson, B.A., Wolf, H., 1988. The antigenic index: a novel algorithm for predicting antigenic determinants. Computer Applications in The Biosciences 4, 181-186. Journal of Molecular Biology 157, 105-132. Jansen, G., 1999. Receptor- and carrier-mediated transport systems for folates and antifolates. Exploitation for folate chemotherapy and immunotherapy. In: Jackman, A.L. (Ed.), Anticancer Development Guide: Antifolate Drugs in Cancer Therapy. Humana Press, New Jersey, USA, pp. 293-321. Johns, D.G., Spertis, S., Burgen, A.S., 1961. The disposal of tritiated folic acid injected intravenously in man. Canadian Medical Association Journal 84, 77-79. Jones, M., Cordell, J.L., Beyers, A.D., Tse, A.G., Mason, D.Y., 1993. Detection of T and B cells in many animal species using cross-reactive anti-peptide antibodies. Journal of Immunology 150, 5429-5435. Josting, A., Diehl, V., Engert, A., 1998. Methotrexat. Der Onkologe 4, 974-985. Kager, L., Cheok, M., Yang, W., Zaza, G., Cheng, Q., Panetta, J.C., Pui, C.H., Downing, J.R., Relling, M.V., Evans, W.E., 2005. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics.The Journal of Clinical Investigation 115, 110-117. Kersey, J.H., 1998. Fifty years of studies of the biology and therapy of childhood leukemia. Blood 92, 1838. Kiupel, M., Teske, E., Bostock, D., 1999.Prognostic factors for treated canine malignant lymphoma. Veterinary Pathology 36, 292-300. Kneuer, C., Honscha, K.U., Honscha, W., 2005. Rat reduced-folate carrier-1 is localized basolaterally in MDCK kidney epithelial cells and contributes to the secretory transport of methotrexate and fluoresceinated methotrexate. Cell and Tissue Research 320, 517-524. Kumar, C.K., Nguyen, T.T., Gonzales, F.B., Said, H.M., 1998. Comparison of intestinal folate carrier clone expressed in IEC-6 cells and in Xenopus oocytes. The American Journal of Physiology 274, 289-294. Kühnel, J.M., Chiao, J.H., Sirotnak, F.M., 2000. Contrasting effects of oncogene expression on two carrier-mediated systems internalizing folate compounds in Fisher rat 3T3 cells. Journal of Cellular Physiology 184, 364-372. Lee, J.J., Hughes, C.S., Fine, R.L., Page, R.L., 1996. P-glycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance. Cancer 77, 1892-1898. Levy, A.S., Sather, H.N., Steinherz, P.G., Sowers, R., La, M., Moscow, J.A., Gaynon, P.S., Uckun, F.M., Bertino, J.R., Gorlick, R., 2003. Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study. Journal of Pediatric Hematology/oncology 25, 688-695. Liu, M., Ge, Y., Cabelof, D.C., Aboukameel, A., Heydari, A.R., Mohammad, R., Matherly, L.H., 2005. Structure and regulation of the murine reduced folate carrier gene: identification of four noncoding exons and promoters and regulation by dietary folates. The Journal of Biological Chemistry 280, 5588-5597. Lucock, M., 2000. Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. Molecular Genetics and Metabolism 71, 121-138. Lémann, M., Zenjari, T., Bouhnik, Y., Cosnes, J., Mesnard, B., Rambaud, J.C., Modigliani, R., Cortot, A., Colombel, J.F., 2000. Methotrexate in Crohn's disease: long-term efficacy and toxicity. The American Journal of Gastroenterology 95, 1730-1734. MacEwen, E.G., Patnaik, A.K., Wilkins, R.J., 1977.Diagnosis and treatment of canine hematopoietic neoplasms. The Veterinary Clinics of North America 7, 105-118. Malik, S.M., Liu, K., Qiang, X., Sridhara, R., Tang, S., McGuinn, W.D. Jr., Verbois, S.L., Marathe, A., Williams, G.M., Bullock, J., Tornoe, C., Lin, S.C., Ocheltree, T.,Vialpando, M., Kacuba, A., Justice, R., Pazdur, R., 2010. Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary. Clinical Cancer Research 16, 4921-4927. Marconato, L., 2011. The staging and treatment of multicentric high-grade lymphoma in dogs: a review of recent developments and future prospects. The Veterinary Journal 188, 34-38. Matherly, L.H., Goldman, D.I., 2003. Membrane transport of folates. Vitamins and Hormones 66, 403-456. Matherly, L.H., Hou, Z., Deng, Y., 2007. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Reviews 26, 111-128. Matus, R.E., Leifer, C.E., MacEwen, E.G., Hurvitz, A.I., 1986. Prognostic factors for multiple myeloma in the dog. Journal of the American Veterinary Medical Association 188, 1288-1292. Mellor, P.J., Haugland, S., Murphy, S., Smith, K.C., Holloway, A., Archer, J., Powell, R.M., Polton, G.A., Tasker, S., McCormick, D., Tempest, M.E., McNeil, P.E., Scase, T.J., Knott, C.D., Bonfanti, U., Villiers, E.J., Argyle, D.J., Herrtage, M.E., Day, M.J., 2006. Myeloma-related disorders in cats commonly present as extramedullary neoplasms in contrast to myeloma in human patients: 24 cases with clinical follow-up. Journal of Veterinary Internal Medicine 20, 1376-1383. Moscow, J.A., Gong, M., He, R., Sgagias, M.K., Dixon, K.H., Anzick, S.L., Meltzer, P.S., Cowan, K.H., 1995. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Research 55, 3790-3794. Movva, S., Alluri, R.V., Venkatasubramanian, S., Vedicherla, B., Vattam, K.K., Ahuja, Y.R., Hasan, Q., 2011. Association of methylene tetrahydrofolate reductase C677T genotype with type 2 diabetes mellitus patients with and without renal complications. Genetic Testing and Molecular Biomarkers 15, 257-261. O'Connor, O.A., Horwitz, S., Hamlin, P., Portlock, C., Moskowitz, C.H., Sarasohn, D., Neylon, E., Mastrella, J., Hamelers, R., Macgregor-Cortelli, B., Patterson, M., Seshan, V.E., Sirotnak, F., Fleisher, M., Mould, D.R., Saunders, M., Zelenetz, A.D., 2009. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. Journal of Clinical Oncology 27, 4357-4364. Pastor, M., Chalvet-Monfray, K., Marchal, T., Keck, G., Magnol, J.P., Fournel-Fleury, C., Ponce, F., 2009. Genetic and environmental risk indicators in canine non-Hodgkin's lymphomas: breed associations and geographic distribution of 608 cases diagnosed throughout France over 1 year. Journal of Veterinary Internal Medicine 23, 301-310. Pinkerton, C.R., 1983. Is folate absorption impaired by high dose methotrexate? British Journal of Cancer 47, 303-305. Ponce, F., Magnol, J.P., Ledieu, D., Marchal, T., Turinelli, V., Chalvet-Monfray, K.,Fournel-Fleury, C., 2004.Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. Veterinary Journal 167, 158-166. Ponce, F., Marchal, T., Magnol, J.P., Turinelli, V., Ledieu, D., Bonnefont, C., Pastor, M., Delignette, M.L., Fournel-Fleury, C., 2010. A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. Veterinary Pathology 47, 414-433. Robien, K., 2005. Folate during antifolate chemotherapy: what we know... and do not know. Nutrition in Clinical Practice 20,411-422. Rojas, H.C., Merino, M.C., Ghiringhelli, M.J.P., Rodríguez, A.J.R., Martínez, L.F., Jensen, R.W., 2011. Lymphomas associated with human immunodeficiency virus infection: retrospective review of medical records. Revista Medica de Chile 139, 27-35. Rosenberg, M.P., Matus, R.E., Patnaik, A.K., 1991. Prognostic factors in dogs with lymphoma and associated hypercalcemia. Journal of Veterinary Internal Medicine 5, 268-271. Said, H.M., Chatterjee, N., Haq, R.U., Subramanian, V.S., Ortiz, A., Matherly, L.H., Sirotnak, F.M., Halsted, C., Rubin, S.A., 2000. Adaptive regulation of intestinal folate uptake: effect of dietary folate deficiency. American Journal of Physiology 279, 1889-1895. Said, H.M., Ghishan, F.K., Redha, R., 1987. Folate transport by human intestinal brush-border membrane vesicles. The American Journal of Physiology 252. 229-236. Said, H.M., Strum, W.B., 1983. A pH-dependent, carrier-mediated system for transport of 5-methyltetrahydrofolate in rat jejunum. The Journal of Pharmacology and Experimental Therapeutics 226, 95-99. Santoro, D., Marsella, R., Hernandez, J., 2007. Investigation on the association between atopic dermatitis and the development of mycosis fungoides in dogs: a retrospective case-control study. Veterinary Dermatology 18, 101-106. Selhub, J., Rosenberg, I.H., 1981. Folate transport in isolated brush border membrane vesicles from rat intestine. The Journal of Biological Chemistry 256, 4489-4493. Shapiro, P.E., Pinto, F.J., 1994. The histologic spectrum of mycosis fungoides/Sézary syndrome (cutaneousT-cell lymphoma): a review of 222 biopsies, including newly described patterns and the earliest pathologic changes. American Journal of Surgical Pathology 18, 645-667. Shelton, G.H., Grant, C.K., Cotter, S.M., Gardner, M.B., Hardy, W.D. Jr., DiGiacomo, R.F., 1990. Feline immunodeficiency virus and feline leukemia virus infections and their relationships to lymphoid malignancies in cats: a retrospective study (1968-1988). Journal of Acquired Immune Deficiency Syndromes 3, 623-630. Simon, D., Moreno, S.N., Hirschberger, J., Moritz, A., Kohn, B., Neumann, S., Jurina, K., Scharvogel, S., Schwedes, C., Reinacher, M., Beyerbach, M., Nolte, I., 2008. Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma. Journal of the American Veterinary Medical Association 232, 879-885. Sirotnak, F.M., Goutas, L.J., Jacobsen, D.M., Mines, L.S., Barrueco, J.R., Gaumont, Y., Kisliuk, R.L., 1987. Carrier-mediated transport of folate compounds in L1210 cells. Initial rate kinetics and extent of duality of entry routes for folic acid and diastereomers of 5-methyltetrahydrohomofolate in the presence of physiological anions. Biochemical Pharmacology 36, 1659-1667. Sirotnak, F.M., Tolner, B., 1999. Carrier-mediated membrane transport of folates in mammalian cells. Annual Review of Nutrition 19, 91-122. Spector, R., Johanson, C.E., 2010. Vectorial ligand transport through mammalian choroid plexus. Pharmaceutical Research 27, 2054-2062. Stokstad, E.L.R., 1990. Historical perspective on key advances in the biochemistry and physiology of folates. In Picciano, M.F., Stokstad, E.L.R., Greogory, J.F. (Ed.), A Folic Acid Metabolism in Health and Disease. Wiley, New York, USA, pp. 1-21. Sweiry, J.H., Yudilevich, D.L., 1985. Transport of folates at maternal and fetal sides of the placenta: lack of inhibition by methotrexate. Biochimica et Biophysica Acta 821, 497-501. Tappin, S.W., Taylor, S.S., Tasker, S., Dodkin, S.J., Papasouliotis, K., Murphy, K.F., 2011. Serum protein electrophoresis in 147 dogs. The Veterinary Record 168, 456. Teske, E., 1994. Canine malignant lymphoma: a review and comparison with human non-Hodgkin's lymphoma. The Veterinary Quarterly 16, 209-219. Tomiyasu, H., Takahashi, M., Fujino, Y., Ohno, K., Tsujimoto, H., 2010.Gastrointestinal and hematologic adverse events after administration of vincristine, cyclophosphamide, and doxorubicin in dogs with lymphoma that underwent a combination multidrug chemotherapy protocol. The Journal of Veterinary Medical Science 72, 1391-1397. Vail, D.M., Young, K.M., 2013. Hematopoietic tumors. In: Withrow, S.J., Vail, D.M., editors. Withrow and MacEwen's Small Animal Clinical Oncology, fifth ed. W.B. Saunders, St. Louis, USA, pp. 608-678. Vezzali, E., Parodi, A.L., Marcato, P.S., Bettini, G., 2010. Histopathologic classification of 171 cases of canine and feline non-Hodgkin lymphoma according to the WHO. Veterinary and Comparative Oncology 8, 38-49. Wang, Y., Zhao, R., Russell, R.G., Goldman, I.D., 2001. Localization of the murine reduced folate carrier as assessed by immunohistochemical analysis. Biochimica et Biophysica Acta 13, 49-54. Weiss D.J., 2006. A retrospective study of the incidence and the classification of bone marrow disorders in the dog at a veterinary teaching hospital (1996-2004) Journal of Veterinary Internal Medicine 20, 955-961. Whetstine, J.R., Flatley, R.M., Matherly, L.H., 2002. The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter. The Biochemical Journal 367, 629-640. Whetstine, J.R., Matherly, L.H., 2001. The basal promoters for the human reduced folate carrier gene are regulated by a GC-box and a cAMP-response element/AP-1-like element. Basis for tissue-specific gene expression. The Journal of Biological Chemistry 276, 6350-6358. Whitehead, V.M., Shuster, J.J., Vuchich, M.J., Mahoney, D.H. Jr., Lauer, S.J., Payment, C., Koch, P.A., Cooley, L.D., Look, A.T., Pullen, D.J., Camitta, B., 2005. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia 19, 533-536. Widemann, B.C., Adamson, P.C., 2006. Understanding and managing methotrexate nephrotoxicity. The Oncologist 11, 694-703. Williams, F.M., Flintoff, W.F., 1995. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. The Journal of Biological Chemistry 270, 2987-2992. Williams, F.M., Murray, R.C., Underhill, T.M., Flintoff, W.F., 1994. Isolation of a hamster cDNA clone coding for a function involved in methotrexate uptake. The Journal of Biological Chemistry 269, 5810-5816. Worm, J., Kirkin, A.F., Dzhandzhugazyan, K.N., Guldberg, P., 2001. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. The Journal of Biological Chemistry 276, 39990-40000. Zachariae, H., 1990. Methotrexate side-effects. The British Journal of Dermatology 36, 127-133. Zain, J.M., O'Connor, O., 2010. Targeted treatment and new agents in peripheral T-cell lymphoma. International Journal of Hematology 92, 33-44. Zeng, H., Liu, G., Rea, P.A., Kruh, G.D., 2000. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Research 60, 4779-4784. Zhang, L., Taub, J.W., Williamson, M., Wong, S.C., Hukku, B., Pullen, J., Ravindranath, Y., Matherly, L.H., 1998. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy. Clinical Cancer Research 4, 2169-2177. Zhang, L., Wong, S.C., Matherly, L.H., 1998. Transcript heterogeneity of the human reduced folate carrier results from the use of multiple promoters and variable splicing of alternative upstream exons. The Biochemical Journal 332, 773-780. Zhao, R., Goldman, I.D., 2003. Resistance to antifolates. Oncogene 22, 7431-7457. zur Hausen, H., Schulte-Holthausen, H., Klein, G., Henle, W., Henle, G., Clifford, P., Santesson, L., 1970. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228, 1056-1058.
摘要: 還原葉酸載體(reduced folate carrier, RFC)是細胞輸入葉酸及抗葉酸藥物的最主要運輸物,其在人和齧齒動物各種組織的基因表現已被建立,至今在犬卻少有研究 本研究的主要目的包含 (一) 建構能增幅犬部分 RFC 基因的聚合酶鏈鎖反。應(polymerase chain reaction, PCR)引子及 (二) 偵測犬正常和淋巴瘤組織的 RFC基因表現量。研究樣本包含 5 隻安死術犬而得的 35 種正常組織及 22 個犬淋巴瘤組織。由這些組織萃取 RNA 後反轉錄為 cDNA,再利用 PCR 增幅出 RFC 基因。將電泳下 RFC 條帶亮度與甘油醛-3-磷酸脱氢酶(glyceraldehyde 3-phosphatedehydrogenase, GAPDH)相除,獲得定量的 RFC 基因表現量。 研究結果顯示 RFC在犬正常組織間幾乎都有表現,但表現程度不一,於中樞神經系統及免疫系統可見比平均更高的表現量 犬淋巴瘤組織的 RFC 表現量則遠低於正常淋巴組織(P <。0.001),且多中心型 B 細胞淋巴瘤、多中心型 T 細胞淋巴瘤及皮膚型 T 細胞淋巴瘤之表現量並無顯著差異。整體而言,RFC 於各種組織間的廣泛分佈支持其在體內葉酸平衡的重要性 而犬淋巴瘤組織的低表現量可能因複雜的機制應組織及,環境的不同做調整,尚須進一步證明。
Reduced folate carrier (RFC) is the main carrier which transports folates and antifolates into the cell. RFC gene expression in human and rodent tissues had been established, however, it has not been revealed in dogs yet. The aims of the present study were: (1) to construct specific PCR primers for amplification of canine RFC gene; (2) to assess RFC gene expressions in normal canine and lymphomas tissues. Thirty-five kinds of normal canine tissues were collected from five euthanized dogs and twenty-two lymphomas were enrolled. Total RNA were extracted from normal and lymphoma tissues, and were transcripted reversely to complementary DNA, and then were evaluated for RFC expressions using polymerase chain reaction. RFC expression levels were obtained from quantified bands of RFC divided by glyceraldehyde 3-phosphate dehydrogenase. It was shown that RFC transcripts were expressed ubiquitously but various levels. Higher expressions were observed in central nervous and immune system than the median of all tested tissues. Expressions of RFC in normal lymphoid tissues were significantly higher when compared to B- or T-cell lymphomas (P < 0.001). And there were no significant difference among multicentric B-cell lymphomas, multicentric T-cell lymphomas, and cutaneous T-cell lymphomas. We concluded that the ubiquitous distribution with various levels of RFC in 35 kinds of normal canine tissues and malignant tissues. Higher expressions were observed in central nervous, immune, and urinary systems than others. Stomach had the highest RFC expression, followed by cerebellum and brain stem, with very low levels in duodenum and cardiac muscle. And expressions of RFC were significantly lower in all cases of lymphomas when compared to normal lymphatic organs (thymus, palatine tonsil, lymph node), which composed mainly of lymphocytes.
URI: http://hdl.handle.net/11455/93053
其他識別: U0005-2105201514540500
文章公開時間: 10000-01-01
Appears in Collections:獸醫學系所

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.